Last reviewed · How we verify
Albumin 20% and terlipressin
Albumin 20% and terlipressin is a Small molecule drug developed by Amany Mousa Salama Muhammed. It is currently in Phase 1 development. Also known as: Microcirculation.
At a glance
| Generic name | Albumin 20% and terlipressin |
|---|---|
| Also known as | Microcirculation |
| Sponsor | Amany Mousa Salama Muhammed |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Evaluating Mesenchymal Stem Cell Therapy in Non-viral Acute on Chronic Liver Failure (ACLF) Patient- Phase-II Trial (PHASE2)
- National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Evaluating Mesenchymal Stem-Cell (MSC) Therapy in Non-viral Acute on Chronic Liver Failure (ACLF) Patients - Phase-III Trial (PHASE3)
- Microcirculation Recruitment Using Albumin 20% and Terlipressin in Septic Patients (PHASE1)
- To Study the Influence of GCSF on Natural History of Acute On Chronic Liver Failure After the Acute Phase (NA)
- Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic Response (PHASE4)
- The Effect of Terlipressin in the Prevention of Type 2 Hepatorenal Syndrome by Improving Mean Arterial Pressure (PHASE4)
- Terlipressin Given As I.V. Boluses Versus Terlipressin Given As Continuous Intravenous Infusion In Patients With Cirrhosis And Type 1 Hepatorenal Syndrome (PHASE2, PHASE3)
- Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Albumin 20% and terlipressin CI brief — competitive landscape report
- Albumin 20% and terlipressin updates RSS · CI watch RSS
- Amany Mousa Salama Muhammed portfolio CI
Frequently asked questions about Albumin 20% and terlipressin
What is Albumin 20% and terlipressin?
Albumin 20% and terlipressin is a Small molecule drug developed by Amany Mousa Salama Muhammed.
Who makes Albumin 20% and terlipressin?
Albumin 20% and terlipressin is developed by Amany Mousa Salama Muhammed (see full Amany Mousa Salama Muhammed pipeline at /company/amany-mousa-salama-muhammed).
Is Albumin 20% and terlipressin also known as anything else?
Albumin 20% and terlipressin is also known as Microcirculation.
What development phase is Albumin 20% and terlipressin in?
Albumin 20% and terlipressin is in Phase 1.
Related
- Manufacturer: Amany Mousa Salama Muhammed — full pipeline
- Also known as: Microcirculation
- Compare: Albumin 20% and terlipressin vs similar drugs
- Pricing: Albumin 20% and terlipressin cost, discount & access